Drug
Vadadustat clinical trials
Also written AKB-6548, MT-6548 and Vafseo.
- studies test it
- 39
- open now
- 2
- in phase 3
- 16
- first study started
- 2010
Keep track of what changes. Save the vadadustat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
39 studies that test it; most in 2018 (10)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 10 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 11
- Phase 3
- 16
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 35 · Other 4
Akebia Therapeutics (31) · Tanabe Pharma Corporation (4) · USRC Kidney Research (1) · The University of Texas Health Science Center, Houston (1) · Mackay Memorial Hospital (1) · Paul Potnuru (1)
Often tested with
Tested in the same studies.
Rifampin (1) · Probenecid (1) · Furosemide (1) · Adefovir (1) · Digoxin (1) · Rabeprazole (1) · Simvastatin (1) · Rosuvastatin (1)
Studies
Open first, then newest update. How each study uses vadadustat is read from its arms, and is right about nine times in ten.
Testing it · 39
- Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung InjuryRecruitingPhase 2/3Paul PotnuruNCT07086755Written as Vadadustat 900mg
- Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis PatientsNot yet recruitingPhase 4Mackay Memorial HospitalNCT07537816Written as Vadadustat
- To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisCompletedPhase 3Akebia TherapeuticsNCT06901505Written as Vadadustat
- Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanCompletedPhase 3Tanabe Pharma CorporationNCT03329196Written as MT-6548
- Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanCompletedPhase 3Tanabe Pharma CorporationNCT03402386Written as MT-6548
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in JapanCompletedPhase 3Tanabe Pharma CorporationNCT03461146Written as MT-6548
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in JapanCompletedPhase 3Tanabe Pharma CorporationNCT03439137Written as MT-6548
- Vafseo Outcomes In-Center ExperienceActive, not recruitingPhase 3USRC Kidney ResearchNCT06520826Written as Vadadustat
- Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating AgentsWithdrawnPhase 3Akebia TherapeuticsNCT05082584Written as Vadadustat
- Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney DiseaseWithdrawnPhase 3Akebia TherapeuticsNCT05082571Written as vadadustat
- Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)CompletedPhase 3Akebia TherapeuticsNCT04313153Written as Vadadustat
- Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)CompletedPhase 2The University of Texas Health Science Center, HoustonNCT04478071Written as vadadustat
- Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis SubjectsCompletedPhase 3Akebia TherapeuticsNCT04707768Written as Vadadustat
- Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin AlfaCompletedPhase 2Akebia TherapeuticsNCT03799627Written as Vadadustat
- 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedPhase 2Akebia TherapeuticsNCT01906489Written as AKB-6548
- Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedPhase 3Akebia TherapeuticsNCT02865850Written as Vadadustat
- 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedPhase 2Akebia TherapeuticsNCT01381094Written as AKB-6548
- Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedPhase 2Akebia TherapeuticsNCT01235936Written as AKB-6548
- 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic HemodialysisCompletedPhase 2Akebia TherapeuticsNCT02260193Written as AKB-6548
- Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4CompletedPhase 2Akebia TherapeuticsNCT04707573Written as Vadadustat
See all 39 studies that test vadadustat →
Given in every arm · 2 — vadadustat is usual care beside what is tested
Codes
What other systems call vadadustat · ClinicalTrials.gg INT000816
- MeSH (NLM) C000624313vadadustatOne source NLM
- UNII (FDA) I60W9520VVVADADUSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27280485vadadustatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152811VadadustatOne source FDA
- DrugBank DB12255One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000624313 | vadadustat | One source NLM |
| UNII (FDA) | I60W9520VV | VADADUSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27280485 | vadadustat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152811 | Vadadustat | One source FDA |
| DrugBank | DB12255 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.